Literature DB >> 27668764

Rapid identification of cytokine release syndrome after haploidentical PBSC transplantation and successful therapy with tocilizumab.

C Cho1,2, M A Perales1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27668764      PMCID： PMC5924416          DOI： 10.1038/bmt.2016.229

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  8 in total

1.  Peripheral blood hematopoietic stem cells for transplantation of hematological diseases from related, haploidentical donors after reduced-intensity conditioning.

Authors:  Kavita Raj; Antonio Pagliuca; Kenneth Bradstock; Victor Noriega; Victoria Potter; Matthew Streetly; Donal McLornan; Majid Kazmi; Judith Marsh; John Kwan; Gillian Huang; Lisa Getzendaner; Stephanie Lee; Katherine A Guthrie; Ghulam J Mufti; Paul O'Donnell
Journal:  Biol Blood Marrow Transplant       Date:  2014-03-18       Impact factor: 5.742

2.  High fever occurring 4 to 5 days post-transplant of haploidentical bone marrow or peripheral blood stem cells after reduced-intensity conditioning associated with the use of post-transplant cyclophosphamide as prophylaxis for graft-versus-host disease.

Authors:  Paul O'Donnell; Kavita Raj; Antonio Pagliuca
Journal:  Biol Blood Marrow Transplant       Date:  2014-10-15       Impact factor: 5.742

3.  Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia.

Authors:  Marco L Davila; Isabelle Riviere; Xiuyan Wang; Shirley Bartido; Jae Park; Kevin Curran; Stephen S Chung; Jolanta Stefanski; Oriana Borquez-Ojeda; Malgorzata Olszewska; Jinrong Qu; Teresa Wasielewska; Qing He; Mitsu Fink; Himaly Shinglot; Maher Youssif; Mark Satter; Yongzeng Wang; James Hosey; Hilda Quintanilla; Elizabeth Halton; Yvette Bernal; Diana C G Bouhassira; Maria E Arcila; Mithat Gonen; Gail J Roboz; Peter Maslak; Dan Douer; Mark G Frattini; Sergio Giralt; Michel Sadelain; Renier Brentjens
Journal:  Sci Transl Med       Date:  2014-02-19       Impact factor: 17.956

4.  Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.

Authors:  Stephan A Grupp; Michael Kalos; David Barrett; Richard Aplenc; David L Porter; Susan R Rheingold; David T Teachey; Anne Chew; Bernd Hauck; J Fraser Wright; Michael C Milone; Bruce L Levine; Carl H June
Journal:  N Engl J Med       Date:  2013-03-25       Impact factor: 91.245

5.  HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide.

Authors:  Leo Luznik; Paul V O'Donnell; Heather J Symons; Allen R Chen; M Susan Leffell; Marianna Zahurak; Ted A Gooley; Steve Piantadosi; Michele Kaup; Richard F Ambinder; Carol Ann Huff; William Matsui; Javier Bolaños-Meade; Ivan Borrello; Jonathan D Powell; Elizabeth Harrington; Sandy Warnock; Mary Flowers; Robert A Brodsky; Brenda M Sandmaier; Rainer F Storb; Richard J Jones; Ephraim J Fuchs
Journal:  Biol Blood Marrow Transplant       Date:  2008-06       Impact factor: 5.742

6.  Haploidentical transplantation using T cell replete peripheral blood stem cells and myeloablative conditioning in patients with high-risk hematologic malignancies who lack conventional donors is well tolerated and produces excellent relapse-free survival: results of a prospective phase II trial.

Authors:  Scott R Solomon; Connie A Sizemore; Melissa Sanacore; Xu Zhang; Stacey Brown; H Kent Holland; Lawrence E Morris; Asad Bashey
Journal:  Biol Blood Marrow Transplant       Date:  2012-08-01       Impact factor: 5.742

7.  Improved early outcomes using a T cell replete graft compared with T cell depleted haploidentical hematopoietic stem cell transplantation.

Authors:  Stefan O Ciurea; Victor Mulanovich; Rima M Saliba; Ulas D Bayraktar; Ying Jiang; Roland Bassett; Sa A Wang; Marina Konopleva; Marcelo Fernandez-Vina; Nivia Montes; Doyle Bosque; Julianne Chen; Gabriela Rondon; Gheath Alatrash; Amin Alousi; Qaiser Bashir; Martin Korbling; Muzaffar Qazilbash; Simrit Parmar; Elizabeth Shpall; Yago Nieto; Chitra Hosing; Partow Kebriaei; Issa Khouri; Uday Popat; Marcos de Lima; Richard E Champlin
Journal:  Biol Blood Marrow Transplant       Date:  2012-07-11       Impact factor: 5.742

8.  Severe Cytokine-Release Syndrome after T Cell-Replete Peripheral Blood Haploidentical Donor Transplantation Is Associated with Poor Survival and Anti-IL-6 Therapy Is Safe and Well Tolerated.

Authors:  Ramzi Abboud; Jesse Keller; Michael Slade; John F DiPersio; Peter Westervelt; Michael P Rettig; Stephanie Meier; Todd A Fehniger; Camille N Abboud; Geoffrey L Uy; Ravi Vij; Kathryn M Trinkaus; Mark A Schroeder; Rizwan Romee
Journal:  Biol Blood Marrow Transplant       Date:  2016-06-16       Impact factor: 5.742
  8 in total
  5 in total

1.  Early administration of cyclosporine may reduce the incidence of cytokine release syndrome after HLA-haploidentical hematopoietic stem-cell transplantation with post-transplant cyclophosphamide.

Authors:  Naoki Kurita; Tatsuhiro Sakamoto; Takayasu Kato; Manabu Kusakabe; Yasuhisa Yokoyama; Hidekazu Nishikii; Mamiko Sakata-Yanagimoto; Naoshi Obara; Yuichi Hasegawa; Shigeru Chiba
Journal:  Ann Hematol       Date:  2021-02-12       Impact factor: 3.673

Review 2.  In the Eye of the Storm: Immune-mediated Toxicities Associated With CAR-T Cell Therapy.

Authors:  Jorge Garcia Borrega; Philipp Gödel; Maria Adele Rüger; Özgür A Onur; Alexander Shimabukuro-Vornhagen; Matthias Kochanek; Boris Böll
Journal:  Hemasphere       Date:  2019-03-29

3.  Pretransplant active disease status and HLA class II mismatching are associated with increased incidence and severity of cytokine release syndrome after haploidentical transplantation with posttransplant cyclophosphamide.

Authors:  Jacopo Mariotti; Daniela Taurino; Fabrizio Marino; Stefania Bramanti; Barbara Sarina; Lucio Morabito; Chiara De Philippis; Clara Di Vito; Domenico Mavilio; Carmelo Carlo-Stella; Matteo Della Porta; Armando Santoro; Luca Castagna
Journal:  Cancer Med       Date:  2019-11-08       Impact factor: 4.452

Review 4.  Cytokine release syndrome.

Authors:  Alexander Shimabukuro-Vornhagen; Philipp Gödel; Marion Subklewe; Hans Joachim Stemmler; Hans Anton Schlößer; Max Schlaak; Matthias Kochanek; Boris Böll; Michael S von Bergwelt-Baildon
Journal:  J Immunother Cancer       Date:  2018-06-15       Impact factor: 13.751

Review 5.  Targeting the NLRP3 Inflammasome in Severe COVID-19.

Authors:  Tracey L Freeman; Talia H Swartz
Journal:  Front Immunol       Date:  2020-06-23       Impact factor: 7.561
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.